Zur Startseite Makuladegeneration

MERITAGE-Studie - Therapie der Alterbedingten Makuladegeneration (AMD)

Publikationen MERITAGE-Studie

20.10.2010 onemedplace.com

NeoVista's Macular Degeneration Device Improves Visual Acuity in Yearlong Study

Medical device company NeoVista, Inc., recently announced one-year results from its MERITAGE study in patients with wet age-related macular degeneration, a leading cause of vision loss in older Americans. Researchers found that a single treatment with the California-based company's EpiRetinal Brachytherapy device stabilized visual acuity in 79 percent of patients, while nearly half of patients experienced improved visual acuity.


16.10.2010 sure-start.com

New Hope In Treatment Of Wet AMD

NeoVista, Inc. made public today at the American Academy of Ophthalmology meeting the company's one-year results from their MERITAGE Study. This study was designed to examine NeoVista's novel Epimacular Brachytherapy procedure when used in patients who require chronic therapy with anti-VEGF agents on an ongoing basis to control Neovascular Age-Related Macular Degeneration (Wet AMD).